CTP is a small peptide naturally found in the body as a portion of the hormone hCG, and in fact provides hCG with its superior longevity. We attach CTP to other proteins and significantly increase their lonevity as well. hCG, a female hormone that helps maintain pregnancy has a much longer life-span than that of the hormone LH, which assists in helping females get pregnant and males to produce testosterone, and is identical to hCG except for the CTP portion. hCG is a natural part of the female system, and males are exposed to it during the 9-month pregnancy period. Therefore, CTP has strong potential to be non-toxic and non-immunogenic to humans when attached to other proteins, while still getting the job done: prolonging the life-span of many other hormones, enzymes and peptides.
"I think Prolor is a great little company, and its small size is one of its main virtues. It is run and managed carefully by hard-working people who get things done efficiently. They currently have half-a-dozen drugs under development, each of which has the potential for over $1 billion in sales."
Data Show PROLOR’s Biobetter Form of hGH has Potential to Reduce Required Dosing Frequency from One Injection Per Day to Two Injections Per Month. Phase I Safety and Tolerability Endpoints Met.
Merck and PROLOR are Both Licensees of the CTP Technology Used to Prolong the Duration of Merck’s Novel Fertility Drug ELONVA®. Supports the Clinical Efficacy and Safety of CTP Technology.
Primate Study Shows Durability of PROLOR’s IFN-Beta-CTP Is Prolonged 13 Times and Drug Exposure is Prolonged 55 Times Compared to Commercially Available IFN-Beta. By Decreasing Frequency of Required Injections, IFN-Beta-CTP Could Provide Important Benefits to Multiple Sclerosis Patients
Chairman & CEO of NYSE, Duncan L. Niederauer, hosted a breakfast and bell-ringing ceremony to celebrate PROLOR's recent listing with NYSE